Sharon Pagano has become vice president, business development and alliances of Cambridge, Mass.-based Genstruct. Pagano was previously senior director of business development and marketing of Incyte — a position she took on after the company’s acquisition of Proteome. She holds a BS in biology from Merrimack College and an MS in pharmaceutical cell biology from the University of Minnesota.
Charles Lillis has been appointed to the board of directors of Boulder, Colo.-based SomaLogic. Lillis is currently also on the board of the food retailer SuperValu and the natural gas company Williams. He is the co-founder of the private equity group LoneTree Capital. He was previously CEO of Media One Group, and has served as dean of the college of business at the University of Colorado. He holds a bachelor’s degree and MBA from the University of Washington and a PhD in business from the University of Oregon.
John Rodriguez has become senior vice president of human resources at Invitrogen. Rodriguez previously worked with human resources management for PepsiCo, Allied Signal, and Home Depot. He holds a bachelor’s degree in psychology from William Patterson University, a master’s degree in organizational psychology from Columbia University, and an MBA from Case Western Reserve University.
John Wilson has been appointed to the scientific advisory board of Winnipeg, Manitoba-based Miraculins. Wilkins is also currently director of the Manitoba Center for Proteomics and is a professor of immunology at the University of Manitoba. He is also the project leader of the Canadian Institutes of Health Research Biomedical Proteomics Program. He holds a PhD in cellular immunology.
Philip Leder, head of the department of genetics at Harvard Medical School, has been elected to the board of directors at Schering-Plough. Leder is also a senior investigator of the Howard Hughes Medical Institute, and is an honorary trustee of the Massachusetts General Hospital, chairman of the Board of the Charles A. Revson Foundation, a trustee of the Foundation for Advanced Education in the Sciences, and a member of the Hadassah Medical Organization. He held research positions at the NIH between the early 1960s and 1980, when he joined the faculty at Harvard.
Metin Colpan will step down from his role as managing director and CEO of Qiagen to become senior technology advisor to the company, while Peer Schatz, current managing director and chief financial officer, will become the new CEO, the company announced this week. The transition will take place over the next two months. Qiagen has also formed a new executive committee, which will consist of: Peer Shatz, Joachim Schorr, Bernd Uder, Roland Sackers, Michael Collasius, Aeneas Marxen, and Uli Schriek.
Michiel de Haan has resigned from his position as vice chairman of the supervisory board for Crucell. De Haan served as vice chairman since the company’s incorporation in October 2000 and was on the board of IntroGene prior to that. De Haan was also a managing partner at Atlas Venture for 20 years.